Foundayo (orforglipron)
Direct answer
What you need to know
Evidence strength: StrongFoundayo is orforglipron, a GLP-1 receptor agonist approved for chronic weight management and given as a daily tablet. Orforglipron — a non-peptide small molecule rather than a peptide, which is why it is the one tablet with no food or water timing restriction.
Key takeaways
- Molecule: orforglipron. Approved for: chronic weight management.
- Form: daily tablet. Prescription-only, like every product in this class.
- Pivotal trial: 12.4% mean body-weight reduction in ATTAIN-1.
Important limitation: This page does not reproduce Foundayo’s label. Side-effect rates, contraindications, dosing schedules and interactions belong to the prescribing information, and we link to the class-wide guides rather than paraphrasing a label.
Next action: The label for Foundayo is published on DailyMed and is the authority on how it is taken. Separately, here is how Foundayo is priced on each route.
Primary sources: DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration
General education, not medical advice. This page does not publish dosing instructions.
At a glance
- Molecule
- orforglipron
- Approved for
- chronic weight management
- Form
- daily tablet
- Self-pay, direct from manufacturer
- from $149/month
- Pivotal trial result
- 12.4% mean weight reduction
- Prescription required
- Yes — as for every GLP-1 receptor agonist
That 12.4% is a group average, and averages in these trials sit on top of a wide spread — some participants lost a great deal more, some lost nothing, and a share of the placebo arm lost weight too. Rather than restate the mean as though it were a forecast, we show the spread behind Foundayo’s trial average, including how many people reached each threshold and what the comparator arm did.
Approved April 2026. The first GLP-1 pill with no food or water timing restrictions.
What it costs
LillyDirect self-pay from $149/month for the 0.8 mg dose. The card for people whose commercial insurance does not cover Foundayo is dose-tiered: $149 (0.8 mg), $199 (2.5 mg), $299 (higher doses).
Verified 2026-08-21 against Foundayo (Eli Lilly). Prices in this category change frequently — confirm before you buy.
That is the manufacturer’s direct price. How it compares against insurance, Medicare and telehealth memberships — which carry a membership fee on top of the medication — is set out in the same figure reached four other ways.
What this page deliberately leaves out
Side-effect rates, contraindications, dosing schedules, and drug interactions for Foundayo are on its FDA-approved label, published on DailyMed. We are not going to reproduce them here from anywhere else, because a drug page that looks complete but was assembled second-hand is more dangerous than one that is visibly partial.
What we do cover, at the level of the class rather than the product:
- Side effects — what is common, what is serious, and the boxed warning.
- Dosing and titration — why doses start low and climb, and what happens at each step.
- How these medications work — the four mechanisms, and why they also explain the side effects.
Questions people ask about Foundayo
Is Foundayo a GLP-1?
Yes. Foundayo is orforglipron, a GLP-1 receptor agonist, approved for chronic weight management and given as a daily tablet. "GLP-1" is the drug class; orforglipron is the molecule; Foundayo is the brand name that molecule is sold under for this use.
Do you need a prescription for Foundayo?
Yes, in the United States, as for every GLP-1 receptor agonist. Anything sold as Foundayo without a prescription is not Foundayo, whatever the label says — and a product bought outside the prescribing chain carries none of the manufacturing verification the approved product does.
How much does Foundayo cost?
Foundayo is published at from $149 a month self-pay direct from the manufacturer, verified 2026-08-21. That figure is the manufacturer's published price, not what you will necessarily pay: insurance, telehealth membership fees and dose all change the total.
How much weight did people lose on Foundayo in its trial?
ATTAIN-1 reported a mean body-weight reduction of 12.4% (first non-peptide oral GLP-1; FDA approved April 2026). That is a group average from one trial over a fixed period, not a forecast for any individual, and trials of different products were run separately rather than head to head.
Before you act on anything here
- Foundayo is prescription-only. Anything sold as Foundayo without a prescription is not Foundayo.
- Take dosing and administration from the label on your own prescription, not from this page or any other.
- Approval status and price are checked on the dates shown and both change — re-verify before relying on either.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved indication and dosage form for Foundayo, and the labelled information this page deliberately does not reproduce.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status for Foundayo, checkable in Drugs@FDA and the Orange Book.
- Lilly's Oral GLP-1 Orforglipron Demonstrated Meaningful Weight LossEli LillySupports: The 12.4% mean body-weight reduction reported for Orforglipron (Foundayo) in ATTAIN-1 · N>3,100 · 72 weeks.
- Foundayo published self-pay pricingFoundayo (Eli Lilly)Supports: The $149/month self-pay price. Verified 2026-08-21.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.